Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Arrowhead Pharmaceuticals (ARWR) over the last 13 years, with Sep 2025 value amounting to $7.5 million.

  • Arrowhead Pharmaceuticals' Capital Expenditures fell 69.03% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year decrease of 83.95%. This contributed to the annual value of $22.7 million for FY2025, which is 83.95% down from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Capital Expenditures stood at $7.5 million, which was up 218.23% from $2.4 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Capital Expenditures' 5-year high stood at $68.7 million during Q4 2023, with a 5-year trough of $2.4 million in Q2 2025.
  • Its 3-year average for Capital Expenditures is $27.5 million, with a median of $24.3 million in 2024.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 573.43% in 2022, then crashed by 89.05% in 2024.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Capital Expenditures stood at $5.8 million in 2021, then soared by 573.43% to $38.9 million in 2022, then skyrocketed by 76.44% to $68.7 million in 2023, then tumbled by 89.05% to $7.5 million in 2024, then tumbled by 69.03% to $7.5 million in 2025.
  • Its Capital Expenditures stands at $7.5 million for Q3 2025, versus $2.4 million for Q2 2025 and $5.3 million for Q1 2025.